Franco L.
- Country
- Italy
- Department
- Area Clinica di Oncoematologia,Terapia cellulare,Terapie geniche e Trapianto Emopoietico e Trial
Research Overview
- A Phase I/II Study of Pembrolizumab (MK-3475) in children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
- Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia
- Revumenib in Combination with Fludarabine and Cytarabine for Pediatric Refractory or Relapsed KMT2A-r, NUP98-r, or NPM1-mut Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 326 of 515 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of acute leukemia, with particular focus on pediatric and young adult patients. Their research encompasses both B-cell and T-cell malignancies, including innovative approaches for relapsed and refractory cases.
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Myeloid Leukemia (CML)
- B-cell Lymphomas
Advanced Therapeutics
The investigator works extensively with novel therapeutic approaches, including CAR-T cell therapy and targeted molecular treatments. Their research includes the application of gene modification techniques and immunotherapy.
- Chimeric Antigen Receptor T-cell therapy
- Tyrosine Kinase Inhibitors
- Gene-Modified Cell Therapies
- Monoclonal Antibodies
Blood Disorders
The investigator studies various non-malignant blood disorders, focusing on genetic and acquired conditions. Their work includes research on rare blood diseases and immune system disorders.
- Sickle Cell Disease
- Beta Thalassemia
- Neutropenic Disorders
- Langerhans Cell Histiocytosis
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.